(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance - 2I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- 3Opening Innovativeness: Moving Thoughts and Tasks
- 4'Crammed into a cell with vermin at New Year'
- 5Flu season is just beginning, but doctors are already on high alert
- Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- Great DSLR Cameras for Photography Devotees
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- 6 Hints to Upgrade Your Charm, In addition to Your Mentality
- Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- What happened to Eleven after the ambiguous 'Stranger Things' series finale? Millie Bobby Brown knows — but 'swore herself to secrecy'
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- Weight-loss pill approval set to accelerate food industry product overhauls
